Abstract
Pituitary dwarfism in recent years has become a completely treatable disease. Somatotropic insufficiency cannot be cured, but can be completely compensated by substitution therapy. With timely started and properly conducted treatment, persons with this disease can achieve normal growth and have a good quality of life. This is a huge achievement of modern medicine. In recent years, against the backdrop of the development of molecular genetics and genetic engineering, significant advances have been made in studying the mechanisms of expression and deciphering the structure of somatotropic hormone (STH) and STG receptor gene genes, and regulating the synthesis of various insulin-like growth factors (IGFs) and their binding proteins.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
